Investor Home

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>

Recent Newsmore >
08/10/16
Nabriva to Present at the 2016 Wedbush PacGrow Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Dr. Colin Broom, Nabriva’s Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 2:30p.m. Eastern ... 
08/09/16
Nabriva Reports Second Quarter 2016 Financial Results
LEAP 2 clinical trial initiated in second quarter Reiterates expectation of top-line data from both CABP phase 3 trials in the second half of 2017 VIENNA, Austria and KING OF PRUSSIA, Pa., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today reported its financial resu... 
07/25/16
Nabriva Announces Nomination of Candidates for Its Supervisory Board
VIENNA, Austria, and KING OF PRUSSIA, Pa., July 25, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, announced today the nominations of Daniel Burgess, Mark Corrigan, M.D., and Stephen Webster to stand for election as new members of its Supervisory Board at the company’s Annual Gener... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.